Csl vifor and travere therapeutics announce sparsentan receives positive chmp opinion for the treatment of iga nephropathy

Committee for medicinal products for human use (chmp) recommends approval of the conditional marketing authorization (cma) for sparsentan for the treatment of iga nephropathy (igan) in europe positive chmp opinion is based on pivotal phase-iii protect study results european commission decision is expected in q2 2024 st. gallen, switzerland , feb. 23, 2024 /prnewswire/ -- csl vifor and travere therapeutics, inc., (nasdaq: tvtx) today announced that the european medicines agency's (ema) chmp has recommended approval of sparsentan for the treatment of adults with primary igan with a urine protein excretion >1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).
TVTX Ratings Summary
TVTX Quant Ranking